DURAVYU’s Phase 3 LUGANO trial missed its prespecified primary endpoint, and EYPT shares lost nearly 67% of their value in a single session. Levi & Korsinsky is investigating on behalf of shareholders who may have legal rights arising from those losses
NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) — Roughly 67% of EyePoint Pharmaceuticals (NASDAQ: EYPT) share value was erased in one trading session after the Company disclosed that DURAVYU missed the prespecified primary endpoint — change in best-corrected visual acuity versus on-label aflibercept — in the Phase 3 LUGANO wet AMD trial. If you held EYPT shares through that decline, you have legal rights and there is no cost to have your losses reviewed. Shareholders who lost money are encouraged to have their EYPT losses reviewed now, or contact Joseph E. Levi, Esq. by email at [email protected] or by telephone at (212) 363-7500.
On March 25, 2026, President and CEO Jay S. Duker was quoted as saying they were “highly confident in the results of these trials [including Phase 3 LUGANO] at this point for a lot of reasons.” On June 9, he reiterated that they “remain quite confident and quite optimistic in the results, and we think we can make a difference for patients,” while claiming the company was “underappreciated” at the time as a “derisked asset.”
Shareholder rights in matters like this are time-sensitive. EYPT investors who suffered losses may speak with an attorney about their options at no charge, or call (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
Frequently Asked Questions About the EYPT Investigation
Q: Who is eligible to participate in the EYPT investigation? A: Investors who purchased EyePoint Pharmaceuticals stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.
Q: How much did EYPT stock drop? A: When the market opened, EYPT shares were down $10.69, or approximately 72.47%, following the EyePoint’s release of topline results in the Phase 3 LUGANO wet AMD trial for DURAVYU. By end of day the drop had settled to a loss of around $9.88, or about 67%. Investors who purchased shares and suffered losses may be eligible to seek a recovery.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether EyePoint Pharmaceuticals made materially false or misleading statements regarding the status and characterization of its Phase 3 wet AMD program. When the Company disclosed the LUGANO primary endpoint failure, the stock price declined sharply.
Q: What do EYPT investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What is a lead plaintiff and why does it matter? A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.
Q: What if I already sold my EYPT shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought EYPT and sold at a loss may still participate in the investigation.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
